Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Morphosys AG O.N. (MORG)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
67.7000 0.0000    0.00%
11:35:13 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  DE0006632003 
WKN:  663200
  • Volume: 122,004
  • Bid/Ask: 67.7000 / 67.7500
  • Day's Range: 67.6500 - 67.8500
Morphosys AG 67.7000 0.0000 0.00%

Morphosys AG O.N. Company Profile

 
Get an in-depth profile of Morphosys AG O.N., including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

544

Equity Type

ORD

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company’s product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren’s disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Contact Information

Address Semmelweisstrasse 7
Planegg, 82152
Germany
Phone 49 89 899 27-0
Fax 49 89 899 27-222
Web www.morphosys.com

Top Executives

Name Age Since Title
Marc Cluzel 69 2012 Independent Chairman of the Supervisory Board
Sergio A. Quezada 48 2016 Member of Scientific Advisory Board
George S. Golumbeski 67 2018 Independent Deputy Chairman of Supervisory Board
Bruce D. Cheson - 2016 Member of Scientific Advisory Board
Andrew Cheng 57 2022 Independent Member of Supervisory Board
Gunther R. Adolf - 2016 Member of Scientific Advisory Board
Krisja Vermeylen 62 2017 Independent Member of the Supervisory Board
Michael Brosnan 69 2018 Independent Member of the Supervisory Board
Raymond W. Sweet - 2016 Member of Scientific Advisory Board
Sharon Curran 56 2019 Independent Member of Supervisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

MORG Comments

Write your thoughts about Morphosys AG O.N.
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
gowtham kotha
gowtham kotha Nov 14, 2022 5:21AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I would like to buy this. Any suggestions.
Reply
0 1
Report
Robert Kable
Robert Kable Nov 14, 2022 5:21AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Negative clinical trials results… not sure if 31% doen warranted, but good to investigate first.
Reply
0 0
Report
gowtham kotha
gowtham kotha Nov 14, 2022 5:21AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Thankyou for the details. Also results shall be out tomorrow.
Reply
0 0
Report
gowtham kotha
gowtham kotha Nov 14, 2022 5:21AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Let me wait and see
Reply
0 0
Report
gowtham kotha
gowtham kotha Jun 29, 2022 8:36AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Why its going down
Reply
0 0
Report
Robert Laszlo
Robert Laszlo Aug 18, 2021 11:11AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
from now it will move up above 50 ...
Reply
2 1
Report
Fa We
Fa___We Aug 18, 2021 11:11AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Obviously you were wrong.
Reply
1 0
Report
Robert Laszlo
Robert Laszlo Aug 18, 2021 11:11AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
in Aug moved up over 50 and i sold all shares at 49.88... now i dont care
Reply
1 0
Report
Bm Bendary
Bm Bendary Aug 02, 2021 7:05AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I wounder why the stock has been hit so hard? Its almost @50% ot march last year when the entire market crashed!! I dont beleive lowering the upper limit of the FY revenue guidance is the driver. I have to say that ive not spent quality time understanding the fundamental of this company, i only strated to follow it recently. Appreciate your insights. Thanks
Reply
0 0
Report
Doe John
Doe John Jul 26, 2021 2:10PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Any idea?
Reply
0 0
Report
Jon Lovbacka
Jon Lovbacka Jul 26, 2021 2:10PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Announced a narrowing of revenue guidance. There are better options out there, but today might be a good entry point as the negative reaction (incl. yesterday) seems excessive.
Reply
0 0
Report
george bush
george bush Apr 21, 2021 9:32AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
https://ch.marketscreener.com/kurs/aktie/MORPHOSYS-AG-436425/news/COMPANY-TALK-J-J-nbsp-41-Prozent-Plus-mit-Morphosys-Wirkstoff-33013409/
Reply
1 0
Report
george bush
george bush Apr 12, 2021 8:37AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
strong buy
Reply
1 0
Report
george bush
george bush Mar 25, 2021 1:06PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
European approval for tafasitamab is due at the end of May
Reply
1 0
Report
Bert Muermans
Bert Muermans Mar 15, 2021 5:42PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Damn good results published!!!
Reply
0 0
Report
Bert Muermans
Bert Muermans Mar 15, 2021 1:19PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
When (what time)  is the news public concerning their yearresults?
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email